{
  "id": "resp_0e82db3a31eef1c100693c804b7b848193a481df16f9ca74b6",
  "object": "response",
  "created_at": 1765572683,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_0e82db3a31eef1c100693c804be8b8819386f5bf6b50babfdc",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c805640688193bdd24e61537055b3",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Recurrent or Metastatic\" \"Triple-negative\" breast cancer CDK12"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c8058c6a4819384e83a9de8ea3d3d",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c806f715c8193b8fb6528b0128f24",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CDK12 inhibitor clinical trial NCT triple negative breast cancer"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c8071a5e081938966f2f751136eb6",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c807619cc819390ee15d850a3683a",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "NCT06600789 CT7439"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c8078e0848193ba3f0942c31048b9",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c807952a88193bfaf35e9a724b4de",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://clinicaltrials.gov/study/NCT06600789"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c807a628081939785fe5d84dc9dcc",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c807c8f888193b2ae5ec0f8bc77d8",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c807dce90819391144a7e432acdca",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c807fa3d881938859b52002f44368",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrials.gov NCT06600789"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c80817d408193975346329c19147e",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c8082cb888193b29ddefdf2988fd3",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "https://clinicaltrials.gov/study/NCT06600789"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c8085076c8193b067997cc7d9fb6c",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c809c4fb48193b0a07c55ae98a19d",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Recurrent or Metastatic\" \"Triple-negative\" \"breast cancer\" trial"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c80a1b73c8193bcd07d37d1287106",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c80c04c6081939d96166b47152a02",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)\""
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c80c4b4148193b2dc78547f1a3aa7",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c80c839cc819395db5fc46f53884a",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "National Cancer Institute triple-negative breast cancer definition"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c80ccdd9481939fc7f8c4d983025e",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c80da26948193bdecccbe4612007d",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "dinaciclib metastatic triple-negative breast cancer clinical trial"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c80e0b2a0819397a6c6c7b996b875",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c80e655f08193853564d7c61825f0",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "NCT01624441 dinaciclib epirubicin metastatic triple negative breast cancer"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c80eb341c81938d86d653a53b6eaa",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c80ec05c88193a6f7b80b44cea119",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "cdek.pharmacy.purdue.edu trial NCT01624441"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c80f0fcf8819387490758d2ed9acc",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c80f17e2c819398b92eb33ff993fd",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "https://cdek.pharmacy.purdue.edu/trial/NCT01624441"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c80f7628081938d6f854c7a0dbeec",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c80fa9ab481938c95e0a481c0de35",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "https://clinicaltrials.gov/study/NCT01624441"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c810035b48193bf5553f426cbaf19",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c8100d1d481938b9940214ad004f7",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrials.gov NCT01624441 study"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c8105cc6081939727235f9b44e5c6",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c8107201c81938d9b6a9e30f65ad8",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "clinicaltrials.gov ct2 show NCT01624441"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c810d8f0c8193898310cc5a0831f1",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c810fc2608193af28f13d5d53d668",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "classic.clinicaltrials.gov NCT01624441"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c8117612081938c5ee91595ce25be",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e82db3a31eef1c100693c8126a17881939f5afd22ff4da8e0",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "dinaciclib developer sponsor Merck SCH 727965"
      }
    },
    {
      "id": "rs_0e82db3a31eef1c100693c812e53608193a655bf79faa47088",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_0e82db3a31eef1c100693c8141eec88193b058940165c6f46e",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [],
          "logprobs": [],
          "text": "{\n  \"validated\": false,\n  \"assets\": [],\n  \"rejected_reason\": \"Candidate identifier \\\"Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)\\\" is an indication/condition (not a specific drug name/code, trial ID, or patent), so sponsor/target/modality/stage/geography cannot be uniquely determined for a single drug asset. TNBC reference: https://www.cancer.gov/types/breast/breast-cancer-types/triple-negative\"\n}"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "xhigh",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 88570,
    "input_tokens_details": {
      "cached_tokens": 4096
    },
    "output_tokens": 11521,
    "output_tokens_details": {
      "reasoning_tokens": 11415
    },
    "total_tokens": 100091
  },
  "user": null,
  "metadata": {}
}